Add spatial control to the ADC toolbox
Byondis combines ADC payload, linker, conjugation, targeting and development capabilities. GenLumina offers a complementary light-activatable intracellular payload modality designed to add control over where cytotoxic activity is switched on.
Target the cell. Deliver the payload. Control activation.
The proposed fit is not intended to replace Byondis’ proprietary ADC platforms. It is to test whether a distinct light-controlled payload modality could expand the range of ADC concepts available for selected programmes.
Select
Choose a suitable internalizing antibody, target or ADC format around a defined tumour setting.
Conjugate
Connect the targeting molecule to GenLumina’s ultra-small DNA–silver nanocluster payload through a compatible linker strategy.
Deliver
Assess binding, conjugate stability, cellular uptake, intracellular localisation and retained payload function.
Activate
Apply controlled local light and measure tumour-cell killing, spatial selectivity and relevant controls.
Molecular targeting determines where the conjugate goes. Light activation is intended to determine where the payload becomes active.
Start with what is demonstrated. Test what is programme-specific.
GenLumina is a preclinical oncology payload-platform company. A Byondis-specific combination has not yet been tested and would require a jointly defined feasibility programme.
Platform foundation
- Light-activated intracellular oncology payload concept
- Targeted and conjugated in-vitro proof-of-concept
- Preclinical work in breast and colorectal cancer models
- Modular antibody- and peptide-targeting approach
- Local activation as an additional control layer
Programme-specific questions
- Suitable antibody, target, indication and model
- Compatible linker and conjugation conditions
- Binding and stability retained after conjugation
- Internalisation and intracellular trafficking
- Light-controlled cytotoxicity and selectivity
Deep ADC capabilities meet a distinct payload-control mechanism
Byondis publicly positions itself around next-generation ADC technology platforms and strategic partnering. GenLumina could offer a complementary payload modality for one carefully selected scientific evaluation.
Byondis develops proprietary payload, linker, conjugation, masking and targeting technologies for next-generation ADCs and novel formats.
Its in-house discovery, preclinical, clinical, CMC and GMP manufacturing capabilities could support rigorous evaluation and later development.
Byondis explicitly invites licensing agreements, research partnerships, combination studies and commercialisation agreements with research and biopharma organisations.
The public Glycotope agreement shows that Byondis has previously used an evaluation framework with an option to in-license selected antibodies for ADC development.
One programme. One decision-oriented proof-of-concept.
A practical first collaboration could focus on one Byondis-selected internalizing antibody or ADC format, with the scientific question, materials, controls and success criteria agreed before experimental work begins.
Can GenLumina’s light-activatable payload be integrated into a relevant Byondis-selected format while preserving targeting and enabling controlled intracellular tumour-cell killing?
Suggested work package
- Select one target, antibody or compatible format and define the intended tumour setting
- Agree material requirements, linker strategy, controls and technical success criteria
- Assess conjugation, binding, stability, uptake and intracellular localisation
- Evaluate light-dependent cytotoxicity, non-activated controls and spatial selectivity
- Review the data jointly and decide whether to progress to in-vivo validation and an option pathway
Evaluate first. Create an option to advance.
The commercial framework can be discussed alongside the PoC so that successful technical validation leads to a clear decision rather than a new negotiation from zero.
Define fit
Agree the programme, molecule, technical question, work plan and decision criteria.
Run PoC
Generate a partner-specific data package under agreed confidentiality and IP terms.
Decide
Use the agreed criteria to determine whether the combination merits further development.
Option pathway
Following success, advance a separately negotiated option or programme-specific licence by target, indication or field.
Explore a focused ADC payload evaluation
GenLumina can prepare a non-confidential scientific overview and propose an initial decision-oriented work package around a suitable Byondis-selected antibody or format.